Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Horcajada, J. P. Articles by Mensa, J. Search for Related Content PubMed PubMed Citation Articles by Horcajada, J. P. Articles by Mensa, J.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, January 2004, p. 142-146, Vol. 11, No. 1
1071-412X/04/$08.00+0     DOI: 10.1128/CDLI.11.1.142-146.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Evaluation of Inflammatory and Renal-Injury Markers in Women Treated with Antibiotics for Acute Pyelonephritis Caused by Escherichia coli

Juan P. Horcajada,^1* María Velasco,¹ Xavier Filella,² Luisa Alvarez,² Elisa De Làzzari,³ Jose Luis Marín,² Blanca Collvinent,⁴ Alex Smithson,¹ Jose Antonio Martínez,¹ Mariana Noguero,¹ Jordi Vila,⁵ and Josep Mensa¹

Service of Infectious Diseases,¹ Service of Microbiology, Institut Clínic Infeccions i Immunologia,⁵ Service of Clinical Biochemistry, Centre de Diagnostic Biomedic,² Biostatistics and Epidemiology Unit,³ Emergency Room, Hospital Clínic Universitari-IDIBAPS, Barcelona, Spain⁴

Received 13 June 2003/ Returned for modification 21 August 2003/ Accepted 9 October 2003

Top Abstract Introduction Materials and Methods Results Discussion References

 
The evolution and the relationship between inflammatory and renal-injury markers in women with acute uncomplicated pyelonephritis under antimicrobial therapy were investigated in a prospective study. Markers were measured before and 6 and 24 h after the intravenous administration of 1 g of ceftriaxone. Before treatment, the median levels of all markers except the serum creatinine levels were high. Twenty-four hours after the onset of antibiotic treatment, the C-reactive protein (CRP) level continued to be high, while the serum interleukin-6 (IL-6) levels and the urine IL-6, IL-8, albumin, and immunoglobulin G (IgG) levels decreased significantly. In contrast, serum creatinine and tumor necrosis factor alpha levels and urine N-acetyl-ß-glucosaminidase, ₁-microglobulin, and ß₂-microglobulin levels did not change over time. There was a significant correlation between IL-6 and IL-8 levels and urine albumin and IgG levels (urine albumin and IgG levels are glomerular and urinary tract-injury markers) as well as between serum CRP levels and the levels of the tubular-injury markers. In women with acute pyelonephritis, appropriate antibiotic treatment rapidly decreases serum IL-6 levels and urine IL-6 and IL-8 levels, which correlate well with urine albumin and IgG levels.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Although acute pyelonephritis (APN) causes less morbidity in adults than in the pediatric population, in which APN may lead to renal scars and altered renal function and/or arterial hypertension (3), little is known about the magnitude of renal damage caused by APN in adults or its relationship to the inflammatory process. This is interesting because the antibiotics used to treat infections caused by gram-negative bacteria may exert a proinflammatory effect via endotoxin release, and this effect can be stronger or weaker, depending on the class of antibiotic used (21, 22). Hence, in APN and other more severe infections caused by gram-negative bacteria, it is conceivable that an antibiotic-induced systemic response and/or organ injury mediated by inflammation may occur (16, 22). This could have implications in adult patients with a high risk of renal insufficiency, such as patients with one kidney, renal transplant recipients, or patients with advanced cirrhosis.

Elevations of urine and serum cytokine levels have been observed in patients with different forms of urinary tract infection (UTIs), especially those with upper UTIs (11, 15). Interleukin-6 (IL-6) is an endogenous pyrogen and an activator of acute-phase reactants and lymphocytes (14). In patients with febrile UTIs, IL-6 reflects the degree of inflammatory response in the urinary tract (19). IL-8 is a chemoattractant for neutrophils (1), and in patients with UTIs it has been related to the degree of pyuria and renal scarring (10). A relationship between the degree of inflammation in APN and renal dysfunction and scarring has been reported previously (10, 12, 24). Urinary albumin and immunoglobulin G (IgG) are considered markers of glomerular dysfunction (2, 23). N-Acetyl-ß-glucosaminidase (NAG) is a renal hydrolytic enzyme located primarily in the lysosomal fraction of the renal tubular cell, and in the event of proximal renal tubular damage, its concentration in urine increases (20). Urinary ₁-microglobulin and ß₂-microglobulin have been proposed to be markers of proximal tubular dysfunction (4, 5). Nearly all ₁- and ß₂-microglobulins filtered by the glomerulus are reabsorbed by the proximal tubule; increased urinary excretion of these proteins denotes malfunction of the proximal portion of the renal tubule (7). It has been shown that in the absence of nephrotoxic compounds or previous renal diseases, the urine ₁-microglobulin level is a useful marker of tubular damage in patients with APN (5). In fact, patients with APN have elevated urine ₁-microglobulin levels, whereas patients with cystitis do not (6).

In order to establish the evolution of inflammatory- and renal-injury markers (RIMs) in patients with APN receiving antibiotic therapy, as well as the possible correlation between them, we conducted an observational study with women with uncomplicated APN treated with ceftriaxone.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Women with uncomplicated APN, defined as fever (armpit temperature, >37.9°C), flank pain, and pyuria and a culture of urine positive for a uropathogen (>100,000 CFU/ml) in the absence of urological abnormalities, were randomly selected among patients admitted to the Infectious Diseases Service of a tertiary-care hospital between February 2000 and October 2001. Patients who had taken antibiotics in the previous week and those who were receiving immunosuppressants or nephrotoxic drugs, as well as diabetics and patients with known renal and/or urological diseases, were not included. Serum creatinine levels, the levels of inflammatory markers in serum (C-reactive protein [CRP], tumor necrosis factor alpha [TNF-], and IL-6) and urine (IL-6 and IL-8), and the levels of RIMs in urine (albumin, IgG, NAG, ₁-microglobulin and ß₂-microglobulin) were measured before the intravenous administration of 1 g of ceftriaxone and 6 and 24 h later, before administration of the next dose of ceftriaxone. Oral antibiotics were prescribed when the patients were afebrile, with the results of the antibiogram taken into account.

The levels of TNF- (reference level, <15 pg/ml; Biosource, Europe, Nivelles, Belgium), IL-6 (reference level in serum, <5 pg/ml; Biosource, Europe), and IL-8 (reference level in urine, <126 pg/ml; Immunotech, Marseille, France) (12) were measured by a solid-phase enzyme immunoassay, which was performed on a microtiter plate with a monoclonal antibody directed against the corresponding cytokine. Finally, the amount of substrate turnover was determined colorimetrically by measuring the absorbance, which is proportional to the cytokine concentration. A standard curve was plotted, and the cytokine concentrations in the samples were determined by interpolation from the standard curve. The results for TNF-, IL-6, and IL-8 are given in picograms per milliliter.

Serum CRP levels (reference levels, 0.1 to 0.8 mg/dl) and urine ₁-microglobulin (reference levels, 0.1 to 10 mg/g of creatinine), ß₂-microglobulin (reference levels, 0.1 to 100 U/g of creatinine), and IgG (reference levels, 0.1 to 4.6 mg/g of creatinine) levels were assayed by immunonephelometric methods (Dade Behring, Marburg, Germany). The levels of NAG (reference levels, 0.2 to 4.6 U/g of creatinine) and albumin (reference levels, 0.1 to 15 mg/g of creatinine) in urine were measured by a spectrophotometric kinetic method with 3-cresolsulfonphthaleinyl-N-acetyl-ß-D-glucosaminide sodium salt as the substrate for NAG and by an immunoturbidimetric assay for albumin in a Cobas Mira S analyzer by using kits from Roche Diagnostics (Basel, Switzerland). Levels in urine were normalized to the urine creatinine level. Measurement of the urine creatinine level was performed in the Cobas Mira S analyzer by an assay based on a modified Jaffe method (Roche Diagnostics).

Informed consent was obtained from all patients. The human experimentation guidelines of the Ethics Committee of the Hospital Clínic of Barcelona were followed.

Statistics. Quantitative data are reported as medians (interquartile ranges). Nonparametric tests were used for comparisons because the sample size was small. For each parameter differences among the three time points were estimated by the Wilcoxon signed-rank test: three pairwise comparisons were made, and the Bonferroni adjustment was used to correct the significance level. The correlation between inflammation markers and RIMs at each of the three time points was estimated by using the Spearman coefficient. In this case the level of significance required for each correlation coefficient to be different from zero was 0.05. Statistical analysis was performed with STATA statistical software (release 7.0, 1999; StataCorp., College Station, Tex.).

Top Abstract Introduction Materials and Methods Results Discussion References

 
Twenty-two women with uncomplicated APN were studied. The mean (standard deviation) age was 49.4 (21.8) years. For all but one of the patients the urine culture yielded Escherichia coli. Blood cultures were positive for four patients (18%), with E. coli growing in all of them. Patients were afebrile in a mean (standard deviation) of 1.64 (0.84) days after the onset of antibiotic therapy.

The median (interquartile range [IQR]) levels of inflammation markers in serum and urine before administration of the first dose of 1 g of ceftriaxone and 6 and 24 h later and the significance levels determined by the Wilcoxon signed-rank test are shown in Table 1. At the baseline, the levels of all inflammation markers were 2 to 19 times higher than the reference levels. Serum IL-6, urine IL-6, and urine IL-8 concentrations decreased significantly 24 h after antibiotic administration, with no changes at 6 h. Serum CRP and TNF- levels did not change significantly and remained high during the first 6 and 24 h (Table 1).

View this table: [in this window] [in a new window]

TABLE 1. Levels of inflammation markers at different stages of the study and significance level by Wilcoxon signed-rank test

Median urine RIM levels at the baseline and 6 and 24 h after the administration of 1 g of ceftriaxone and the significance level determined by the Wilcoxon signed-rank test are shown in Table 2. With the exception of urine NAG and serum creatinine levels, RIM levels were high at the baseline. After the onset of antibiotic therapy, the median ₁-microglobulin and ß₂-microglobulin levels in urine at 6 h and the median NAG levels in urine at 24 h were higher than the baseline levels; however, the comparisons of the distributions were not statistically significant. Urine IgG levels decreased significantly after 24 h, with no change at 6 h, while urine albumin levels decreased significantly after 6 and 24 h from the onset of antibiotic treatment. Creatinine levels did not change significantly during the study period (Table 2).

View this table: [in this window] [in a new window]

TABLE 2. Levels of RIMs at different stages of the study and significance level by the Wilcoxon signed-rank test

Table 3 shows the levels of significance of the correlation between each inflammation marker and each RIM at the time points studied. A relation between CRP levels and the levels of tubular-injury markers was found at the three time points: an increment in the CRP level is related to an increment in the tubular-injury marker level. The same kind of relation was found between CRP and urine albumin levels at 6 and 24 h after the onset of treatment.

View this table: [in this window] [in a new window]

TABLE 3. Correlations between the levels and evolution of the inflammation markers and the RIMs

There was no correlation between TNF- levels and the levels of any of the RIMs studied except for urine IgG levels at 6 h. Serum and urine IL-6 levels and urine IL-8 levels correlated well with urine albumin and IgG levels at the three time points studied and with urine ₁-microglobulin, ß₂-microglobulin, and NAG levels at 24 h. Serum IL-6 levels also correlated with urine NAG levels at the baseline, with ß₂-microglobulin levels at 6 h, and with ₁-microglobulin levels at the three time points studied (Table 3).

Top Abstract Introduction Materials and Methods Results Discussion References

 
In the present study we analyzed the local and systemic inflammatory responses in patients with APN as well as the associated renal damage before and after the onset of effective antimicrobial therapy. The levels of the proinflammatory cytokines and CRP were elevated at the baseline. However, during the first 24 h of appropriate treatment a different evolutionary pattern emerged. On the one hand, no changes in TNF- and CRP levels were detected throughout the study period; on the other hand, there was a significant decrease in IL-6 and IL-8 levels after the first 6-h period, during which they were stable. High levels of proinflammatory cytokines have previously been described in patients with upper UTIs (11); however, studies describing the evolving pattern of inflammation in adults with APN during antibiotic treatment are scarce. The rapid decline in serum IL-6 and urine IL-6 and IL-8 levels after the onset of antimicrobial therapy in this study suggests that in women with APN effective antimicrobial therapy significantly reduces the inflammatory process in 24 h. This has recently been reported in children with APN (13). The different patterns of CRP and interleukins can be explained in part by the longer half-life of CRP than those of the interleukins (8, 21) and because in patients with septic conditions the production of proinflammatory cytokines is down-regulated (21). We do not have a satisfactory explanation for the lack of a decline in TNF- levels, but a similar evolutionary profile, despite significant decreases in the levels of other proinflammatory interleukins, has been described previously (21).

One interesting finding of our study is that the urine albumin and IgG levels followed the evolution of the IL-6 and IL-8 levels, respectively, with a significant correlation at the three time points of evaluation used in the study. Although urine IgG and albumin levels can be elevated by the urinary tract inflammatory response itself and could be considered markers of generalized urinary tract inflammation, they can also reflect glomerular damage (2, 23). The correlation between cytokine levels and renal and urinary tract injury may reflect in part the underlying link between bacterial infection, inflammation, and organ injury. In fact, in patients with renal scarring urine IL-8 levels are significantly higher than those in controls (10). Moreover, exogenous administration of cytokines has induced glomerular injury and enhanced renal damage in animals with glomerulonephritis (18). Thus, more renal damage occurs with a stronger inflammatory response. In this regard, it is striking that in our study, 24 h after the onset of effective antimicrobial therapy, IL-6 and IL-8 levels as well as the levels of glomerular and urinary tract-injury markers (urinary albumin and IgG) decreased significantly and nearly reached normal levels. This finding strengthens the importance of starting antimicrobial therapy as early as possible in patients with APN in order to prevent or limit renal injury. The early institution of antibiotic therapy has been shown in previous experiments with animals to mitigate the extent of renal scarring (9). On the other hand, because different antibiotics can induce a more intense or a less intense proinflammatory response (22), it is conceivable that the magnitude of organ injury could depend on the particular antibiotic used. In this regard, a previous study found a nonsignificant increase in proinflammatory cytokine levels 4 h after the administration of a selective PBP 3 binding antibiotic (ceftazidime) which was not observed after treatment with a specific PBP 2 inhibitor (imipenem) in patients with sepsis caused by gram-negative bacteria (21). In the present study we again found that the behavior of TNF- was different from those of IL-6 and IL-8 6 h after the onset of treatment with ceftriaxone, another beta-lactam selective for PBP 3. At that time point, serum TNF- levels tended to be higher than those at the baseline, whereas the interleukin levels were reduced. Although differences in sampling times (4 versus 6 h) can partly justify these discrepancies, we believe that the available data altogether cast some doubts about the real magnitude of the proinflammatory effect attributable to beta-lactams selective for PBP 3 in patients with APN. However, as in previous studies differences between antibiotics were detected (21). This is an area in which additional comparative studies are clearly needed. Another application of the findings of this study is complicated UTIs. It would be valuable to know if a lack of reduction in the levels of these markers of inflammation and renal dysfunction signify an unresolved infection, such as a renal abscess or an infection caused by a drug-resistant microorganism.

The levels of the tubular-injury markers ₁-microglobulin and ß₂-microglobulin were elevated before the onset of antibiotic treatment and remained high during the first 24 h, with no significant changes. NAG levels were not elevated at the first two times of evaluation, but they were increased at 24 h. The elevations in the levels of the tubular-injury markers could be related to glomerular damage. It is known that patients with albuminuria also have elevated levels of ₁- and ß₂-microglobulin excretion but that this situation improves as the albuminuria resolves (17). In our study, however, the levels of the tubular-injury markers did not change, despite the decrease in albuminuria, and correlated well with CRP levels at the three time points. Our findings indicate that in APN patients, tubular damage persists longer than glomerular injury, even if the infection is being controlled. We can only speculate that inflammation-mediated glomerular alteration seems functional in nature and hence improves as the level of inflammation decreases, whereas tubular injury could be structural, as the elevation of the levels of NAG (an intracellular enzyme) suggests. The persistence of tubular dysfunction after injury has previously been shown in patients with other pathologies, such as acute urine retention, in which it may linger for more than 6 months after the obstruction is relieved (17). The importance and consequences of this finding for adults with APN remains to be elucidated. Moreover, urine ₁- and ß₂-microglobulin levels were somewhat higher at 6 h than before the onset of therapy, although not significantly. This could be related to the proinflammatory effect of the antibiotic used (21), although the small change observed together with the lack of a correlation of the tubular-injury marker levels with the levels of TNF- (the only cytokine which showed some increment shortly after the start of treatment) does not support this hypothesis.

From a clinical point of view, our findings indicate the need for further studies aimed at investigating the effects of different classes of antibiotics on renal inflammation and injury when they are used to treat APN. Until this issue is clarified, our findings point to the importance of starting antimicrobial therapy as soon as possible in patients with pyelonephritis to promptly reduce the inflammatory response and, eventually, prevent or limit organ damage.

View this table: [in this window] [in a new window]

 
* Corresponding author. Mailing address: Service of Infectious Diseases. Institut Clínic Infeccions i Immunologia, Hospital Clínic Universitari-IDIBAPS, Villaroel 170, 08036 Barcelona, Spain. Phone: 34 932275708. Fax: 34 934514438. E-mail: jhorcaja{at}clinic.ub.es.

Top Abstract Introduction Materials and Methods Results Discussion References

 

1
1. Baggliolini, M., A. Waltz, and S. L. Kunkel. 1989. Neutrophil activating peptide-I/interleukin-8, a novel cytokine that activates neutrophils. J. Clin. Investig. 84:1045-1047.
2
2. Bergon, E., R. Granados, P. Fernandez-Segoviano, E. Miravalles, and M. Bergon. 2002. Classification of renal proteinuria: a simple algorithm. Clin. Chem. Lab. Med. 40:1143-1150.[CrossRef][Medline]
3
3. Chon, C. H., F. C. Lai, and L. M. Shortliffe. 2001. Pediatric urinary tract infections. Pediatr. Clin. N. Am. 48:1441-1459.[CrossRef][Medline]
4
4. Donaldson, M. D., R. E. Chamber, M. W. Woolridge, and J. T. Whicher. 1990. ₁-Microglobulin, ß₂-microglobulin and retinol binding protein in childhood febrile illness and renal disease. Pediatr. Nephrol. 4:314-318.[CrossRef][Medline]
5
5. Everaert, K., J. Delanghe, C. Vande Wiele, P. Hoebeke, R. A. Dierckx, B. Clarysse, N. Lameire, and W. Oosterlinck. 1998. Urinary alpha 1-microglobulin detects uropathy. A prospective study in 483 patients. Clin. Chem. Lab. Med. 36:309-315.[CrossRef][Medline]
6
6. Everaert, K., A. Raes, O. Hoebeke, W. Samijn, J. Delanghe, C. Vande Wiele, and J. Vande Walle. 1998. Combined use of urinary alpha1-microglobulin and 99mTc DMSA scintigraphy in the diagnosis and follow-up of acute pyelonephritis and cystitis in children. Eur. Urol. 34:486-491.[CrossRef][Medline]
7
7. Flynn, F. V. 1990. Assessment of renal function: selected developments. Clin. Biochem. 23:49-54.[CrossRef][Medline]
8
8. Gabay, C., and I. Kushner. 1999. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340:448-454.[Free Full Text]
9
9. Glauser, M. P., P. Meylan, and J. Billa. 1987. The inflammatory response and tissue damage: the example of renal scars following acute renal infection. Pediatr. Nephrol. 1:615-622.[CrossRef][Medline]
10
10. Haraoka, M., K. Senoh, N. Ogata, M. Furukawa, T. Matsumoto, and J. Kumazawa. 1996. Elevated interleukin-8 levels in the urine of children with renal scarring and/or vesicoureteral reflux. J. Urol. 155:678-680.[CrossRef][Medline]
11
11. Hedges, S., K. Stenqvist, G. Lidin-Janson, J. Martinell, T. Sandberg, and C. Svanborg. 1992. Comparison of urine and serum concentrations of interleukin-6 in women with acute pyelonephritis or asymptomatic bacteriuria. J. Infect. Dis. 166:653-656.[Medline]
12
12. Jacobson, S. H., B. Hylander, B. Wretlind, and A. Brauner. 1994. Interleukin-6 and interleukin-8 in serum and urine in patients with acute pyelonephritis in relation to bacterial-virulence-associated traits and renal function. Nephron 67:172-179.[Medline]
13
13. Kassir, K., O. Vargas-Shiraishi, F. Zaldivar, M. Berman, J. Singh, and A. Arrieta. 2001. Cytokine profiles of pediatric patients treated with antibiotics for pyelonephritis: potential therapeutic impact. Clin. Diagn. Lab. Immunol. 8:1060-1063.[Abstract/Free Full Text]
14
14. Kishimoto, T. 1989. The biology of interleukin-6. Blood 74:1-10.[Free Full Text]
15
15. Ko, Y. C., N. Mukaida, S. Ishiyama, A. Tokue, T. Kawai, K. Matsushima, and T. Kasahara. 1993. Elevated interleukin-8 levels in the urine of patients with urinary tract infections. Infect. Immun. 61:1307-1314.[Abstract/Free Full Text]
16
16. Mock, C. N., G. J. Jurkovich, D. J. Dries, and R. V. Maier. 1995. Clinical significance of antibiotic endotoxin-releasing properties in trauma patients. Arch. Surg. 130:1234-1241.[Abstract/Free Full Text]
17
17. Mustonen, S., I. Ala-Houhala, and T. L. J. Tammela. 1999. Proteinuria and renal function during and after acute urinary retention. J. Urol. 161:1781-1785.[CrossRef][Medline]
18
18. Ortiz, A., M. Gomez-Chiarri, J. Alonso, et al. 1994. The potential role of inflammatory and fibrogenic cytokines in glomerular diseases. J. Lipid Mediat. Cell Signal 9:55-74.[Medline]
19
19. Otto, G., J. Braconier, A. Andreasson, and C. Svanborg. 1999. Interleukin-6 and disease severity in patients with bacteremic and nonbacteremic febrile urinary tract infection. J. Infect. Dis. 179:172-179.[CrossRef][Medline]
20
20. Price, R. G. 1992. The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin. Nephrol. 38(Suppl.):14-19.[Medline]
21
21. Prins, J. M., M. A. van Agtmael, E. J. Kuijper, S. J. H. van Deventer, and P. Speelman. 1995. Antibiotic-induced endotoxin release in patients with gram-negative urosepsis: a double-blind study comparing imipenem and ceftazidime. J. Infect. Dis. 172:886-891.[Medline]
22
22. Prins, J. M., S. J. H. van Deventer, E. D. J. Kuijper, and P. Speelman. 1994. Clinical relevance of antibiotic-induced endotoxin release. Antimicrob. Agents Chemother. 38:1211-1218.[Free Full Text]
23
23. Recker, F., W. Hofmann, A. Bex, and R. Tscholl. 1992. Quantitative determination of urinary marker proteins: a model to detect intrarenal bioeffects after extracorporeal lithotripsy. J. Urol. 148:1000-1006.[Medline]
24
24. Roilides, E., F. Papachristou, E. Gioulekas, S. Tsaparidou, N. Karatzas, J. Sotiriou, and J. Tsiouris. 1999. Increased urine interleukin-6 concentrations correlate with pyelonephritic changes on 99mTc-diercaptosuccinic acid scans in neonates with urinary tract infections. J. Infect. Dis. 180:904-907.[CrossRef][Medline]

---

Clinical and Diagnostic Laboratory Immunology, January 2004, p. 142-146, Vol. 11, No. 1
1071-412X/04/$08.00+0     DOI: 10.1128/CDLI.11.1.142-146.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Smithson, A., Sarrias, M. R., Barcelo, J., Suarez, B., Horcajada, J. P., Soto, S. M., Soriano, A., Vila, J., Martinez, J. A., Vives, J., Mensa, J., Lozano, F. (2005). Expression of Interleukin-8 Receptors (CXCR1 and CXCR2) in Premenopausal Women with Recurrent Urinary Tract Infections. CVI 12: 1358-1363 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Horcajada, J. P. Articles by Mensa, J. Search for Related Content PubMed PubMed Citation Articles by Horcajada, J. P. Articles by Mensa, J.